News Sentiment

DWTX sentiment intelligence

Dogwood Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.42 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -7.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -7.8% over four weeks
Fair value -82.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 32
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 11
Market source 10
Stock Titan 6
TradingView 3
simplywall.st 3
MarketBeat 2
The Standard (HK) 2
marketscreener.com 1

Event Lens

What the news is about

Classified themes
Earnings 19
Market update 18
Deals and strategy 4
Guidance 3
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
SEC.gov Direct company coverage

EDGAR Filing Documents for 0001558370-24-013167

This article provides details of an EDGAR Form 8-K filing (SEC Accession No. 0001558370-24-013167) filed by Virios Therapeutics, Inc. The filing date was October 7, 2024, with a period of report ending October 4, 2024. It covers various items, including material definitive agreem

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 13:40
Source
SEC.gov
Finviz Direct company coverage

DWTX - Dogwood Therapeutics Inc Stock Price and Quote

This page provides a detailed stock quote and company information for Dogwood Therapeutics Inc (DWTX), including its current stock price, financial metrics, insider and institutional ownership, and recent performance. It also lists significant news events and announcements relate

Tone
Negative 40/100
Event
Market update
Published
01 Jun 2026 23:39
Source
Finviz
GlobeNewswire Direct company coverage

Dogwood Therapeutics Announces Worldwide Development and

Dogwood Therapeutics has announced a global development and commercialization partnership with PRIDCor Therapeutics for its anti-viral candidates, IMC-1 and IMC-2, with potential payments of up to $100 million. This agreement allows Dogwood to shift its focus to its lead pain and

Tone
Positive 73/100
Event
Deals and strategy
Published
23 Apr 2026 09:00
Source
GlobeNewswire
Stock Titan Direct company coverage

DWTX - Dogwood Therapeutics Latest Stock News & Market Updates

This page provides comprehensive news and analysis for Dogwood Therapeutics (DWTX), a biopharmaceutical company focused on pain and neuropathy treatments. Key updates include the dosing of the first patient in a Phase 2b trial for Halneuron® for chemotherapy-induced neuropathic p

Tone
Neutral 50/100
Event
Market update
Published
25 Feb 2026 18:51
Source
Stock Titan
GlobeNewswire Direct company coverage

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dogwood Therapeutics, Inc. today announced positive interim results from its Halneuron® Phase 2b clinical trial for chemotherapy-induced neuropathic pain (CINP). The interim analysis of 97 patients showed that Halneuron® treated patients demonstrated separation from placebo in pa

Tone
Positive 82/100
Event
Earnings
Published
22 Dec 2025 10:15
Source
GlobeNewswire